Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) announced solid financial results for the quarter ending September 30, 2024, showcasing strong revenue and profit growth across its global operations. The company’s international business saw remarkable growth, with a 25% increase year-over-year (YoY) and an 18% rise quarter-over-quarter (QoQ).
Key contributors include the Canadian market, which achieved a 51% YoY growth, driven by both the core business and the acquisition of Mantra. The Rest of the World segment also saw a 29% YoY growth, fueled by strong demand in both ARV (Antiretroviral) and non-ARV products.
In Europe, Emcure experienced steady growth of 6%, driven by its expanding base business. The domestic market also performed well, with a 15% increase, reaching ₹933 crore, further boosted by a distribution partnership with Sanofi.
Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, commented on the results, stating, “Our Q2 performance reflects the benefits of significant investments we’ve made in our international and domestic operations over the past two years. Our recent strategic acquisitions, including the Sanofi partnership in India and the Mantra acquisition in Canada, are now fully integrated. Moving forward, our focus is on achieving greater operational synergies and improving margins while continuing to expand market share and launch new products.”
Emcure Pharmaceuticals, a leading Indian pharmaceutical company, was founded in 1981 and is dedicated to developing and marketing high-quality pharmaceutical products worldwide. The company is known for its focus on innovation and patient-centered care, with a broad portfolio spanning multiple therapeutic areas. Ranked as the 12th largest pharma company in India as of June 2024, Emcure has a presence in over 70 countries, including Canada and Europe.
